atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health TherapiesNEW YORK and AMSTERDAM, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (
NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced the successful completion of the strategic combination between atai Life Sciences (“atai”) and Beckley Psytech Limited (“Beckley Psytech”) in an all-share transaction. The combined company brings together world-class science and clinical expertise with a pipeline of investigational psychedelic-based neuroplastogens designed to address some of the most urgent unmet needs in mental health.
